Targeting Nectin-4 sensitizes glioblastoma to temozolomide
Background Temozolomide (TMZ) remains the first-line chemotherapeutic agent for glioblastoma (GBM), but its clinical efficacy is often limited by acquired resistance. This study aimed to investigate whether nectin-4 could serve as a target to sensitize GBM cells to TMZ and to determine whether resveratrol enhances TMZ...